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Abstract
Background: The prevalence of prescribed drugs in survivors of colorectal cancer
(CRC) was evaluated.
Methods: Data from the Cancer Registry of Norway were linked to the Norwegian
Prescription Database for a study population of 3.52 million individuals. Prevalence
ratios (PRs) with 95% confidence intervals (CIs) of prescribed drugs in CRC-survivors
compared to the cancer-free population, were estimated by log-binomial regression,
adjusting for age and education.
Results: Almost 27 000 individuals, aged 20 to 84, were diagnosed with CRC during
2005 to 2014. The first year after diagnosis, the prevalence of prescribed drugs was
higher in CRC-survivors compared with the cancer-free population, especially drugs
for anxiety and tension, and steroid-responsive conditions. PRs for several drugs,
especially drugs used for mental and behavioural disorders, decreased with time since
diagnosis. The prevalence of drugs used for anxiety and tension was elevated
10 years after diagnosis; PRs the first year after diagnosis were 20 (95% CI: 18-22) in
males and 17 (16-18) in females. Ten years after diagnosis PRs were 5.0 (3.1-7.9) and
2.0 (1.0-3.8), respectively. In absolute numbers, the largest increase, compared to the
cancer-free population, was in drugs used for gastric acid disorders and pain. The
prevalence of neuromodulatory drugs was higher in CRC-survivors.
Conclusions: The prevalence of several drugs was higher in CRC-survivors than in
the cancer-free population 10 years after diagnosis. The largest absolute excess in
prevalence was for gastric acid disorder and pain medications, while the relative
Abbreviations: ATC, Anatomical Therapeutic Chemical; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRC, colorectal cancer; CRN, Cancer Registry of Norway; CVD,
cardiovascular disease; DDD, Defined Daily Doses; ICD, International Classification of Diseases; NNED, Norwegian National Education Database; NorPD, Norwegian Prescription Database; PR,
prevalence ratio.
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prevalence of drugs used for anxiety and tension was high in CRC-survivors. Long
persisting neuropathia was indicated.
K E YWORD S
chronic diseases, colorectal cancer, drugs, medication, pharmacoepidemiology, population-based
1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in men
(11% of all cancers worldwide) and the second in women (9.5%).1,2
Norway has the highest incidence of CRC among the Nordic
countries.3
Comorbidities in individuals diagnosed with cancer have recently
been examined in a Danish study; 55% had comorbidities at diagno-
sis.4 In CRC-survivors, approximately one-third suffer from severe
comorbidities at the time of cancer-diagnosis.5 A recent large British
study showed that survivors of most site-specific cancers had
increased risk of one or more cardiovascular disease (CVD) out-
comes6; the CRC-survivors had increased risks of venous thromboem-
bolism and pericarditis.
Adverse long-term effects of CRC and its treatments include
sensory neuropathy after oxaliplatin, gastrointestinal problems,
urinary incontinence, sexual dysfunction, fatigue, anxiety and
fear of recurrence, sleeping problems and depression.7,8 How-
ever, their frequency throughout CRC survivorship needs to be
properly quantified for implementing appropriate preventive
strategies.
This study aimed to examine the prevalence of prescribed drugs,
as a proxy for chronic diseases, in survivors of adult-onset CRC
(≥20 years) in Norway during 2005 to 2014 relative to the cancer-free
population.
2 | MATERIAL AND METHODS
Using unique national ID-numbers, we performed a comprehensive link-
age of records from nationwide databases in Norway (a population of
approximately 5.2 million in 2016); the National Population Registry
(1954-2016),9 the Cancer Registry of Norway (CRN) (1953-2014),10 the
Norwegian Prescription Database (NorPD) (2004-2016),11,12 and the Nor-
wegian National Education Database (NNED) (2004-2014).13 The regis-
tries and the classification systems used are described in the
Supplementary Material.
2.1 | Study population
In all, 3.66 million individuals born during 1920 to 1990 were
living in Norway on January 1st, 2005. Of these, 145 030 were
excluded because they had a history of cancer prior to 2005
and 1737 because they developed cancer, died, or emigrated
before reaching age 20 years (Figure 1). Thus, the final study
population comprised 3.52 million individuals who were
followed up for dispensed drug prescriptions from age 20 or
January 1st, 2005, whichever occurred latest, until emigration
(n = 53 129), a cancer-diagnosis other than CRC (n = 181 853),
age 85 years (n = 182 181), death (n = 174 751) or December
31st, 2016 (n = 2 925 627), whichever occurred earliest.
2.2 | Drugs and diseases
Reimbursed drugs (any reimbursement code; drugs used for chronic
diseases with documented effects) were used as a proxy for the dis-
eases/conditions listed in Table 1,14 which were grouped into five
major categories:
1. Cardiovascular diseases (CVDs)
2. Endocrine, nutritional, and metabolic diseases
3. Diseases of the nervous system
4. Mental and behavioural disorders
5. Other conditions
The selection of drugs examined in this study was primarily based on
a study by Sarfati et al,14 who developed and validated a pharmacy-
Key Points
• Up to 12 years after diagnosis, the use of several drugs,
particularly drugs for anxiety and tension, and steroid-
responsive conditions, was higher in colorectal cancer
(CRC) survivors than in the cancer-free population.
• In absolute terms, the use of drugs for gastric acid disor-
ders and pain was high.
• The prevalence in use of drugs for cardiac arrhythmias
was higher in male CRC-survivors over 60 years than in
younger males, comparing the cancer-free population.
• The prevalence in use of drugs for anxiety and tension,
and for pain was higher for survivors of non-localised than
localised CRC.
• There was a higher prevalence of neuromodulatory drugs
among the CRC-survivors.
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based comorbidity-index in cancer patients. In addition, two more
classes of drugs (sex hormones and urologicals) were included based
on mapping of comorbidities in CRC-patients.7,8,15
2.3 | Statistical analysis
One-year prevalence, hereafter termed prevalence, of drug use (‘use’
defined as dispensed drugs within the period studied irrespective of
prior medication use) within each calendar year 2005 to 2016 was
calculated.
Prevalence ratios (PRs) with 95% confidence intervals (CIs) of
specific reimbursed drugs among CRC-survivors (defined as individ-
uals alive after a CRC-diagnosis), compared to the cancer-free pop-
ulation for each calendar year (2005-2016), were estimated using
log-binomial regression.
In the analyses, the calendar years for cancer-survivors were cat-
egorised into one-year intervals as (<1, 1, 2, …, 9, and ≥10 years)
according to time from cancer-diagnosis to January 1st the actual
year. The year in which the cancer was diagnosed was not included in
any category to ensure that the drugs were used after the cancer-
diagnosis. The year in which the follow-up ended was included only if
the follow-up ended in the second half of that calendar year, but was
excluded if it ended in the first half as individuals would have been
‘under risk’ of using drugs for less than half a year (see Supplementary
Material). The statistical models included adjustments for the potential
confounding effects of age (in 5-year categories: 20-24, 25-29, …, and
80-84 years) and educational level (compulsory (<10 years), interme-
diate (10-12 years) and tertiary (≥13 years)). For the latter variable,
the NNED data for the years 2004, 2009, and 2014 were used,
respectively, for the calendar years 2005-2008, 2009-2013, and
2014-2016. Further adjustment for country of birth (categorised as
Norway, other high-income countries and low-income countries
according to the Global Burden of Diseases, Injuries, and Risk Factors
Study16 did not change the estimates, and was consequently not
included in the final models. PRs in patients stratified by stage of dis-
ease at diagnosis (localised and non-localised), age at diagnosis (<60
and ≥60 years) and subtype of CRC (colon and rectum) were also
calculated.
In addition, age-standardised 1-year prevalence for males and
females was computed for each drug group for the cancer-free popu-
lation (averaged over the study period) and for the CRC-survivors
1 year before and 5 years after the CRC-diagnosis. We used direct
standardisation with the Scandinavian standard population in 5-year
age groups as reference population.17
The statistical analysis was performed in Stata version SE 15.0,
using the cluster command to account for multiple observations per
individual.
F IGURE 1 Selection of the
study population, Norway 2005
to 2016
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2.4 | Ethics approval
The study was approved by the Regional Committee for Medical and
Health Research Ethics (REC South East; no. 2010/131).
3 | RESULTS
Most (91%) of the eligible study population were born in Norway, and
24% had tertiary education in 2005 (increasing to 32% in 2014)
(Table 2). Altogether 26 691 individuals were diagnosed with CRC
(age 20-84 years) during 2005 to 2014; 21% of the cancers were
localised at diagnosis. The number of CRC-survivors by time since
diagnosis is given in Figure 2.
On average, 41% of males and 47% of females in the cancer-
free population aged 30-84 years used at least one of the exam-
ined drugs (with reimbursement) during one calendar year in the
study period (Table 3). The prevalence in CRC-survivors was higher
than in the cancer-free population both in the year prior to the
CRC-diagnosis and 5 years thereafter. The absolute excess in prev-
alence in CRC-survivors compared to the cancer-free population
was especially large for drugs used for gastric acid disorders and
for pain. The prevalence was highest in individuals with low educa-
tion (data not shown), especially for drugs used for psychotic
illness.
Table 3 also gives prevalence of drugs in patients with localised and
non-localised CRC 5 years after diagnosis. The prevalence of drugs used
for anxiety and tension was higher in patients with non-localised CRC
than in patients with localised CRC. The proportions of individuals with
use of two or more of the drug groups explored, were higher in CRC-
survivors (31.3 in males and 32.3 in females) than in the cancer-free pop-
ulation (23.5 in males and 26.2 in females). Male CRC-survivors aged
60 or above had higher prevalence of drugs in general than those diag-
nosed before age 60, mostly due to drugs used for cardiac arrhythmias
(Table S1).
3.1 | The first year after CRC-diagnosis
CRC-survivors had a higher prevalence of drugs in the first year after
diagnosis for all the main drug groups examined (Figure 3), except for
the group of drugs used for endocrine, nutritional, and metabolic dis-
eases. The increased PR of drugs used for CVDs was mainly due to
drugs used for thromboembolism, but prevalence was also higher,
although to a lesser extent, for cardiac arrhythmias and congestive
heart failure (Figure S2). In contrast, the prevalence of drugs for coro-
nary heart disease was lower in CRC-survivors than in the cancer-free
population. The prevalence of drugs for endocrine, nutritional, and
metabolic diseases was slightly lower among CRC-survivors than in
the cancer-free population, reflecting a lower prevalence of drugs for
hyperlipidaemia (Figure S3). The higher prevalence of drugs for diseases
of the nervous system among CRC-survivors was driven by the higher
prevalence of drugs used for epilepsy, including neuromodulatory drugs
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such as carbamazepine, gabapentin, and pregabalin, but there was a lower
prevalence of drugs for Parkinson disease (Figure S4). Altogether 6.4%
used gabapentin, pregabalin or carbamazepine more than 5 years after
diagnosis, and 87% of those not in combination (dispensed within
30 days) with other strong analgesics (opioids). Raised PRs were also
observed for drugs used for several mental and behavioural disorders,
particularly for anxiety and tension (more than 96% of the drugs
were anxiolytics (Anatomical Therapeutic Chemical [ATC]-code:
N05B)); the PRs were 20 (95% CI: 18-22) in males and 17 (16-18)
in females (Figure S5). Among drugs for other conditions, a higher
prevalence was seen for drugs used for gastric acid disorders,
anaemia, steroid responsive conditions, pain, sex hormones and
modulators of the genital system (females) and urologicals (males)
in the CRC-survivors (Figure S6).
3.2 | Ten years after CRC-diagnosis
Ten years after CRC-diagnosis, the prevalence of drugs used for CVDs
overall remained high in CRC-survivors, reflecting mainly use of drugs
for thromboembolism, whilst the prevalence of drugs used for coro-
nary heart disease was still lower than in the cancer-free population.
The overall prevalence of drugs for diseases of the nervous system
was higher in CRC-survivors compared to the cancer-free population,
driven by drugs for epilepsy. The PRs were increased for drugs for
mental and behavioural disorders in general. The largest relative
increase was seen in drugs for anxiety and tension (PR = 5.0 (3.1-7.9)
in males and 2.0 (1.0-3.8) in females).
In the drug group for other diseases/conditions, high PRs were
seen for drugs used for gastric acid disorders, anaemia, steroid
responsive conditions, pain and urologicals (males).
3.3 | Sex-differences
The total prevalence of drugs was about equal in males and females
(Table S2). However, there were some differences for particular drugs.
The prevalence of drugs used for cardiovascular diseases was lower in
females than in males, whereas the prevalence of drugs used for
hypothyroidism, psychotic illness, depression, osteoporosis/Paget dis-
ease and pain was higher in females. The PRs for drugs used for pain
were higher in males than in females.
Sex hormones and modulators of the genital system were more
often used by female CRC-survivors, especially females with rectal
cancer (Table S3), than females in the cancer-free population. In male
CRC-survivors, the prevalence of sex hormones and modulators of the
genital system was increased 2 to 8 years after diagnosis (Figure S6).
The PRs of use of urologicals were elevated in male CRC-survivors until
at least 10 years after diagnosis (Figure S6).
3.4 | Localised vs non-localised cancer
The difference between survivors with localised and non-localised
CRC was especially large during the first 5 years after diagnosis. The
PRs of drugs used for anxiety and tension, and for pain (Figure S7,
Table S4) were higher for survivors of non-localised than localised
CRC. In females, the PRs were also higher for sex hormones in individ-
uals with non-localised CRC.
TABLE 2 Characteristics of the eligible study population and





Male 1 758 395 50.0
Female 1 760 883 50.0
Year of birth
1920-1939 504 226 14.3
1940-1959 1 089 696 31.0
1960-1990 1 925 356 54.7
Country of birtha
Norway 3 211 102 91.2
Other high-income countries 123 941 3.5
Low-income country 182 772 5.2
Missing 1463 0.0
Educationb
Compulsory (<10 years) 1 074 170 30.5
Intermediate (10-12 years) 1 535 940 43.6
Tertiary (≥13 years) 836 718 23.8
Missing 72 450 2.1
Total 3 519 278 100.0
Colorectal cancer patients
(n = 26 691)




70-84 13 102 49.1
Stage
Localised 5638 21.1
Non-localised 20 503 76.8
Unknown 550 2.1
Type of cancer (ICD-10 codec)




aCategorisation based on the classification used in the Global Burden of
Diseases, Injuries, and Risk Factors Study.16
bCategorisation based on information from Statistics Norway.13
Information from 2004 was used for individuals born before 1989, and
information from 2009 was used for individuals born 1989 to 1990.
cInternational Classification of Diseases, version 10.
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PRs were higher for drugs used for anxiety and tension in individ-
uals with localised rectal than localised colon cancer.
4 | DISCUSSION
In this nationwide cohort study, we examined the use of drugs, as a
proxy for chronic diseases, in survivors of CRC up to 12 years after
diagnosis. The prevalence of many drugs was elevated in CRC-
survivors the first year after diagnosis. Ten years after diagnosis, the
prevalence was still elevated.
4.1 | Comparisons with other studies
A literature review in 2013 by Mitchell et al concluded that anxiety
may be a problem in long-term cancer-survivors.18 This accords with
our results, which show an elevated prevalence of drugs used for anxi-
ety and tension more than 10 years after the CRC-diagnosis, espe-
cially in males.
In a Danish study, Kjaer et al focused on risk of incident
hospitalisation for somatic diseases in cancer-survivors diagnosed at
age 40 years or above.19 Colon cancer-survivors had an increased risk
of hospitalisation in most of the diagnostic groups considered. Instead
of hospitalisation, we focused on the prevalence of drugs dispensed
outside institutions by time since diagnosis. Both studies, however,
used population-based registries. Kjaer et al observed that cancer
patients had higher risk of a range of somatic diseases requiring
hospitalisation compared to the cancer-free population. In the first
5 years after diagnosis, colon cancer patients had an increased risk of
hospitalisation due to diseases of the digestive system. We found a
higher prevalence of drugs used for gastric acid disorders in CRC-
survivors compared to the cancer-free population, even more than
10 years after diagnosis. Colon cancer patients had a higher preva-
lence than rectal cancer patients.
Fredheim et al compared the prevalence of analgesics and benzo-
diazepines in individuals with cancer 10 years after diagnosis with the
prevalence in the cancer-free population, in a cross-sectional study
from 2019, using the same data linkage as used in our study.20 They
found that cancer patients in general had a moderately higher preva-
lence of analgesics use 10 years after diagnosis, while in individuals
diagnosed with cancers of the lower gastrointestinal tract (here CRC)
the use was more similar to the cancer-free population. In our study,
we observed an increase both in drugs used for anxiety and tension
(including benzodiazepines) and pain (including analgesics) in CRC-
survivors compared to the cancer-free population.
In 2019, Hawkins et al found an increased risk of endocrine/met-
abolic disorders in CRC-survivors.21 Unfortunately, we did not have
BMI-measurements in our data. However, we observed an increased
prevalence of drugs used for diabetes mellitus (indicated by prescrip-
tion of anti-diabetics [ATC: A10]) in CRC-survivors compared to the
cancer-free population many years after diagnosis.
Sexual dysfunction and urinary incontinence are common among
CRC-survivors.7,8 According to a review by Panjari et al (2012),22
F IGURE 2 Colon and rectal cancer patients under observation by time since diagnosis, Norway 2005 to 2016
1042 ENGELAND ET AL.
TABLE 3 One year prevalence (%) of different groups of drugs (dispensed and reimbursed) in the cancer-free Norwegian population during
2005 to 2016, in addition to the prevalence in colorectal cancer (CRC) patients (at diagnosisa and the fifth year after CRC-diagnosis, both for
























23.0 24.8 27.1 26.5 27.6 20.5 21.7 24.6 22.9 25.3
Cardiac arrhythmias 0.9 1.2 1.3 3.5 0.8 0.4 0.6 0.3 0.3 0.3
Coronary heart disease 2.0 2.1 1.5 1.8 1.3 1.2 1.3 1.0 1.3 0.9
Ischemic heart disease/
hypertension
21.7 23.4 24.9 24.5 25.3 19.3 20.8 20.6 20.8 20.6
Congestive heart failure 3.9 4.5 4.0 3.5 4.2 4.9 6.2 5.5 4.3 6.1
Thromboembolism 5.0 5.2 7.2 7.7 7.1 2.9 2.8 8.1 4.6 9.4
Endocrine, nutritional,
and metabolic diseases
17.8 17.8 17.7 16.4 18.1 18.7 19.5 21.3 28.4 19.7
Diabetes mellitus 4.8 5.3 5.9 4.4 6.5 3.3 3.8 3.4 2.3 3.9
Hyperlipidaemia 14.8 14.5 13.8 13.6 13.8 11.3 11.8 13.4 14.4 12.8
Hypothyroidism 1.6 1.7 1.6 1.5 1.6 7.9 7.8 9.9 15.7 8.8
Diseases of the nervous
system
2.2 2.5 5.7 3.1 6.3 2.6 2.7 4.7 2.9 5.5
Epilepsy 1.9 2.3 5.4 2.5 6.1 2.3 2.5 4.4 2.7 5.2
Parkinson disease 0.4 0.3 0.3 0.6 0.3 0.3 0.3 0.2 0.2 0.3
Mental and behavioural
disorders
6.7 6.6 9.4 7.6 10.0 11.2 10.4 12.3 10.3 13.5
Psychotic illness 2.0 2.3 1.2 1.0 1.4 2.3 1.9 2.4 1.2 3.0
Anxiety and tension 0.3 0.3 2.7 0.8 3.2 0.5 0.5 3.4 1.1 4.3
Depression 5.3 5.4 6.8 6.4 7.0 9.8 9.3 9.2 9.7 9.3
Other diseases/
conditions
19.6 19.2 31.2 35.7 28.1 26.2 25.2 33.6 32.3 35.0
Gastric acid disorders 6.4 6.4 11.7 12.1 11.6 6.4 5.7 10.5 10.6 10.7
Anaemia 1.6 1.6 5.1 6.7 3.6 2.9 2.9 4.7 3.2 5.4
Steroid-responsive
conditions
2.6 3.5 6.5 7.6 5.3 3.4 4.3 6.3 4.3 7.3
Osteoporosis/Paget
disease
0.3 0.4 0.5 0.5 0.5 2.1 2.1 2.5 2.6 2.5








0.2 0.1 1.1 0.5 1.2 0.3 0.5 4.2 4.4 4.3
Urologicals 2.6 1.9 3.6 4.2 3.4 1.6 1.4 2.4 2.1 2.6
At least one above (%) 41.4 42.7 52.3 56.0 49.2 47.3 47.8 54.0 56.0 54.9
At least two above (%) 23.5 24.4 31.3 29.8 31.1 26.2 26.7 32.3 30.8 33.3
Mean number 0.9 0.9 1.2 1.2 1.2 1.0 1.0 1.3 1.3 1.4
Note: The prevalence is age-standardised according to the Scandinavian standard population for ages 30 to 84 years.17
aThe prevalence of a specific drug for all CRC-survivors is mostly between the prevalence in survivors in the groups having localised and non-localised
disease. However, in some cases the prevalence in CRC-survivors in total is not between the prevalence in individuals with localised and non-localised
disease due to different survival in patients with localised, non-localised and unknown stage of disease.
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female rectal cancer patients have sexual function problems. In our
study, the prevalence of sex hormones and modulators of the genital
system was higher in female rectal cancer patients than in the cancer-
free population, and higher PRs were seen in female than in male rec-
tal patients. The prevalence of urologicals was more common in male
CRC-survivors compared to the cancer-free male population.
In a large British population-based cohort study published in
2019, Strongman et al found that survivors of most site-specific can-
cers had increased risk of one or more CVD outcomes.6 They used
data from primary care and hospitals to look at the risk of getting vari-
ous diseases, whereas we explored the prevalence of diseases mea-
sured by drug use. For CRC-patients, Strongman et al found an
increased risk of venous thromboembolism and of pericarditis even
10 years after diagnosis. In our study, including almost twice as many
CRC-survivors, the prevalence of drugs used for thromboembolism
was still elevated more than 10 years after diagnosis. In patients with
cancer and venous thromboembolism, lifelong treatment is often con-
sidered, explaining some of the elevated prevalence of drugs for
thromboembolism many years after diagnosis.23
Oxaliplatin is a central chemotherapeutic drug in the treatment
of CRC but is rarely recommended to patients above 75 years of
age, and recently also rarely above 70. One of its dominating side
effects (peripheral neuropathy) is caused by neurotoxic effects on
the peripheral sensory nervous system. This chemotherapy-
induced peripheral neuropathy reveals symptoms of paresthesia
and dysesthesia, neuropathic pain, and numbness.24 These symp-
toms usually decline with time, but the duration of symptoms has
varied between studies.25 A recent study has shown that up to a
quarter of patients suffered chemotherapy-induced peripheral
neuropathy 5 years after the end of chemotherapy.26 Neu-
romodulatory drugs such as antiepileptics like carbamazepine,
gabapentin, and pregabalin have demonstrated some activity in the
prophylaxis and treatment of oxaliplatin-induced acute neuropa-
thy. In our study, the majority of patients (87%) using neu-
romodulatory drugs were not combining these with other strong
analgesics, indicating that the majority of the CRC-survivors were
not using antiepileptics for pain caused by the cancer itself. These
observations, together with the fact that the increased prevalence
of drugs for diseases of the nervous system in CRC-survivors com-
pared to the cancer-free population persisted up to 10 years after
diagnosis, may indicate persistent neuropathy.
4.2 | Study strengths and limitations
The health care system in Norway covers the entire population, inde-
pendently of socioeconomic status. In 2016, reimbursed drugs consti-
tuted 87% (measured in DDDs) of all prescribed drugs and included in
the NorPD.27
Even though we know when the drugs were dispensed and to
whom, we do not know when or whether the dispensed drugs were
actually used. However, the fact that the drugs were dispensed with
reimbursement indicates an underlying chronic disease. As we were
using drug dispensing as a proxy for chronic diseases, it was irrelevant
whether the drugs were taken or not.
We used population-based registries to explore the prevalence of
drug use in all individuals diagnosed with CRC in Norway (2005-2014)
prospectively up to 12 years after diagnosis. Reporting to the nation-
wide registries is mandatory. The completeness and quality of the
NorPD and CRN are high,10,12 and only 1.5% of the study population
emigrated during follow-up. Hence, this study includes an unselected
group of CRC-patients.
The drugs examined in this study might have been dispensed
for diseases other than those investigated here, or for a combina-
tion of diseases. These drugs may also have been used to prevent
certain conditions (ie, prophylactic treatment preoperatively with
heparin [LMWH]), or when immobilised or together with
chemotherapy.
We had no information on specific cancer treatment for the CRC-
survivors and were thus unable to link adverse health effects to spe-
cific treatments. The main aim of our study was, however, to explore
the prevalence of prescribed drugs, as a proxy for chronic diseases, in
survivors of adult-onset CRC, rather than to examine the complicated
associations between treatment and later health effects. The impact
of different treatments on later health problems must be thoroughly
explored in other studies.
Another limitation is the lack of information on possible con-
founders such as diet, smoking and alcohol consumption. How-
ever, we used information on education as an indicator of
socioeconomic status. Information on cancer incidence was not
available after 2014. Hence, among those regarded as ‘cancer-
free’ after 2014, some individuals were diagnosed with cancer
(estimates from current material indicate that about 1.5% of those
at risk on January 1st, 2015 would have been diagnosed with can-
cer during 2015-2016). If the lack of information on cancer diagno-
ses had any impact on the study results, it would only influence
the PRs in the first 2 years after diagnosis.
Many of the above-mentioned studies examined incidence of
different diseases and hospital admissions, while we examined the
prevalence of drug use. The studies are thus not directly compara-
ble. Our study may detect milder cases, not leading to hospital
visits. However, since NorPD does not contain medications dis-
pensed at hospitals on an individual level, we may underestimate
the total disease burden in the population. Data from the Norwe-
gian Patient Registry could have been used for validating of the
NorPD data. However, such a validation was beyond the aim of
the present study.
In this study, we estimated the prevalence of drug use a specific
year for distinct drugs, disregarding whether the individuals had used
the drugs previously. Since only about 70% of the individuals diag-
nosed with CRC survive 5 years after diagnosis, this group of CRC
patients differ from the total group diagnosed with CRC, not only by
being 5 years older, but also because a larger proportion of those with
advanced stage of cancer at diagnosis have died.
We explored the prevalence of ‘use’ of several specific drugs in
the CRC patients, and the large number of tests were considered
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F IGURE 3 Prevalence ratios* (PRs) for reimbursed drugs in the five main groups** in patients with colorectal cancer compared to the cancer-
free population by time since diagnosis, Norway 2005 to 2016. A, Males; B, Females. *Estimated by log-binomial regression, adjusted for age and
education. **Main groups: 1. Cardiovascular diseases (CVDs) (Cardiac arrhythmias, Coronary heart disease, Ischemic heart disease/hypertension,
Congestive heart failure, Thromboembolism). 2. Endocrine, nutritional, and metabolic diseases (Diabetes mellitus, Hyperlipidaemia,
Hypothyroidism). 3. Diseases of the nervous system (Epilepsy, Parkinson disease). 4. Mental and behavioural disorders (Psychotic illness, Anxiety
and tension, Depression). 5. Other conditions (Gastric acid disorders, Anaemia, Steroid-responsive conditions, Osteoporosis/Paget disease, Pain,
Chronic obstructive pulmonary disease [COPD], Sex hormones and modulators of the genital system, Urologicals)
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while interpreting the results. Due to the huge size of the dataset, the
power was large resulting in narrow confidence intervals. Hence, we
also considered the absolute level of the drug use.
In conclusion, the prevalence of different drugs was higher in
CRC-survivors than in the cancer-free population, especially drugs
used for anxiety and tension, and for steroid-responsive condi-
tions. The absolute excess in prevalence was especially large for
drugs used for gastric acid disorders and for pain, even a decade
after CRC-diagnosis. The prevalence of neuromodulatory drugs
such as gabapentin and pregabalin, was higher in the CRC-
survivors than in the cancer-free population, indicating long
persisting neuropathia. Altogether, our results emphasise the
necessity of special monitoring of CRC-survivors.
ACKNOWLEDGEMENTS
This study was supported by the Norwegian Cancer Society
(182360-2016).
CONFLICT OF INTEREST
The authors have no conflicts of interest and no financial relationships
relevant to this article to disclose.
ETHICS STATEMENT
The study was approved by the Regional Committee for Medical and
Health Research Ethics (REC South East; no. 2010/131).
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
https://doi.org/10.3322/caac.21492.
2. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet.
2019;394(10207):1467-1480. https://doi.org/10.1016/S0140-6736
(19)32319-0 [published Online First: 2019/10/22].
3. Danckert B, Ferlay J, Engholm G, et al. NORDCAN: Cancer Incidence,
Mortality, Prevalence, and Survival in the Nordic Countries, Version
8.2 (26.03.2019): Association of the Nordic Cancer Registries. Danish
Cancer Society, 2019.
4. Loeppenthin K, Dalton SO, Johansen C, et al. Total burden of disease
in cancer patients at diagnosis-a Danish nationwide study of mul-
timorbidity and redeemed medication. Br J Cancer. 2020;123(6):1033-
1010. https://doi.org/10.1038/s41416-020-0950-3 [published
Online First: 2020/07/08].
5. Erichsen R, Horvath-Puho E, Iversen LH, et al. Does comorbidity
interact with colorectal cancer to increase mortality? A nationwide
population-based cohort study. Br J Cancer. 2013;109(7):2005-2013.
https://doi.org/10.1038/bjc.2013.541.
6. Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks
of specific cardiovascular diseases in survivors of 20 adult cancers: a
population-based cohort study using multiple linked UKelectronic
health records databases. Lancet. 2019;394:1049-1054. https://doi.
org/10.1016/S0140-6736(19)31674-5 [published Online First:
2019/08/25].
7. Denlinger CS, Barsevick AM. The challenges of colorectal cancer sur-
vivorship. J Natl Compr Canc Netw. 2009;7(8):883-893.quiz 94.
8. Buccafusca G, Proserpio I, Tralongo AC, et al. Early colorectal can-
cer: diagnosis, treatment and survivorship care. Crit Rev Oncol
Hematol. 2019;136:20-30. https://doi.org/10.1016/j.critrevonc.
2019.01.023.
9. Hammer H. The central population registry in medical research.
Tidsskr Nor Laegeforen. 2002;122(26):2550.
10. Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the can-
cer registry of Norway: an overview of comparability, completeness,
validity and timeliness. Eur J Cancer. 2009;45(7):1218-1231. https://
doi.org/10.1016/j.ejca.2008.10.037.
11. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a
cohort for pharmacoepidemiological research. Basic Clin Pharmacol
Toxicol. 2010;106(2):86-94. https://doi.org/10.1111/j.1742-7843.
2009.00494.x.
12. Berg C, Blix HS, Fenne O, et al. The Norwegian Prescription Database
2013–2017. Oslo, Norway: Norwegian Institute of Public Health;
2018.
13. Statistics Norway. Statistics Norway; 2021 updated 2016. Available
from: ssb.no accessed January 30, 2021.
14. Sarfati D, Gurney J, Stanley J, et al. Development of a pharmacy-
based comorbidity index for patients with cancer. Med Care. 2014;52
(7):586-593. https://doi.org/10.1097/MLR.0000000000000149.
15. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society
colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;
65(6):428-455. https://doi.org/10.3322/caac.21286.
16. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, defini-
tions, and metrics. Lancet. 2012;380(9859):2063-2066. https://doi.
org/10.1016/S0140-6736(12)61899-6.
17. Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age Standardization of
Rates: A New WHO Standard. GPE Discussion Paper Series: No 31.
Geneva, Switzerland: WHO; 2001.
18. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in
long-term cancer survivors compared with spouses and healthy con-
trols: a systematic review and meta-analysis. Lancet Oncol. 2013;14
(8):721-732. https://doi.org/10.1016/S1470-2045(13)70244-4 [pub-
lished Online First: 2013/06/14].
19. Kjaer TK, Andersen EAW, Winther JF, et al. Long-term somatic dis-
ease risk in adult Danish cancer survivors. JAMA Oncol. 2019;5:537–
545. https://doi.org/10.1001/jamaoncol.2018.7192.
20. Fredheim OM, Skurtveit S, Handal M, et al. A complete national
cohort study of prescriptions of analgesics and benzodiazepines
to cancer survivors in Norway 10 years after diagnosis.
Pain. 2019;160(4):852-859. https://doi.org/10.1097/j.pain.
0000000000001459.
21. Hawkins ML, Blackburn BE, Rowe K, et al. Endocrine and metabolic
diseases among colorectal cancer survivors in a population-based
cohort. J Natl Cancer Inst. 2020;112(1):78–86. https://doi.org/10.
1093/jnci/djz040 [published Online First: 2019/03/29].
22. Panjari M, Bell RJ, Burney S, et al. Sexual function, incontinence, and
wellbeing in women after rectal cancer—a review of the evidence.
J Sex Med. 2012;9(11):2749-2758. https://doi.org/10.1111/j.1743-
6109.2012.02894.x.
23. Riess H, Habbel P, Juhling A, et al. Primary prevention and treatment
of venous thromboembolic events in patients with gastrointestinal
cancers - review. World J Gastrointest Oncol. 2016;8(3):258-270.
https://doi.org/10.4251/wjgo.v8.i3.258 [published Online First:
2016/03/19].
24. Kerckhove N, Collin A, Conde S, et al. Long-term effects, pathophysi-
ological mechanisms, and risk factors of chemotherapy-induced
peripheral neuropathies: a comprehensive literature review. Front
Pharmacol. 2017;8:86. https://doi.org/10.3389/fphar.2017.00086
[published Online First: 2017/03/14].
ENGELAND ET AL. 1047
25. Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic
oxaliplatin-induced peripheral neuropathy and the relation with
oxaliplatin administration. Support Care Cancer. 2014;22(7):1999-
2007. https://doi.org/10.1007/s00520-014-2242-z [published
Online First: 2014/04/15].
26. Selvy M, Pereira B, Kerckhove N, et al. Long-term prevalence of
sensory chemotherapy-induced peripheral neuropathy for 5 years
after adjuvant FOLFOX chemotherapy to treat colorectal cancer:
a multicenter cross-sectional study. J Clin Med. 2020;9(8). https://
doi.org/10.3390/jcm9082400 [published Online First: 2020/07/31].
27. Sakshaug S. Legemiddelforbruket i Norge 2012–2016 [Drug Consump-
tion in Norway 2012–2016]. In: Sakshaug S, ed. Legemiddelstatistikk. Oslo,
Norway: Norwegian Institute of Public Health; 2017.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Engeland A, Ghaderi S, dos-Santos-
Silva I, et al. Prescribed drugs in 27 000 individuals after
diagnosis of colorectal cancer: A population-based cohort
study. Pharmacoepidemiol Drug Saf. 2021;30:1037–1048.
https://doi.org/10.1002/pds.5243
1048 ENGELAND ET AL.
